This clinical trial is focused on studying osteoporosis, a condition that weakens bones, making them fragile and more likely to break. The study will compare two treatments: MAB-22 and Prolia, both of which contain the active substance denosumab. Denosumab is a type of protein used to help strengthen bones. The purpose of the study is to see if MAB-22 works as well as Prolia in treating osteoporosis in postmenopausal women.

Participants in the study will receive either MAB-22 or Prolia through a subcutaneous injection, which means the medicine is given under the skin using a pre-filled syringe. The study will last for a period of time, during which the effects of the treatments on bone health will be monitored. This includes looking at changes in bone mineral density, which is a measure of bone strength, and other markers in the blood that indicate bone health.

The study will also assess the safety of the treatments by monitoring any side effects or adverse reactions that may occur. Additionally, the study will look at how the body processes the medication, known as pharmacokinetics, and how the medication affects the body, known as pharmacodynamics. The goal is to ensure that MAB-22 is as effective and safe as Prolia for women with osteoporosis. Participants will be closely monitored throughout the study to ensure their well-being and to gather important data on the treatments’ effects.